Orinove, Inc. clinical trials
A subsidiary of Fosun Pharma
The registry lists 3 studies whose lead sponsor is Orinove, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 30, 2025.
Registry sponsor names on this page
- Orinove, Inc.3 studies
Something wrong with this grouping? Tell us on the Fosun Pharma page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Fosun Pharma studies →
- Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.CompletedNCT05154201Phase 1/2
Sponsor listed in the registry: Orinove, Inc.
- Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)SuspendedNCT04643769Phase 1
Sponsor listed in the registry: Orinove, Inc.
- ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast CancerCompletedNCT03950570Phase 1/2
Sponsor listed in the registry: Orinove, Inc.